Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly Global External R&D Director Yetunde Taiwo On Partnering Plans For Discovery Research: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Yetunde Taiwo, Eli Lilly's global external R&D director, is on a global hunt for molecules that can bolster Lilly's research efforts and arm it with novel therapies. Eli Lilly spends more than $3.4 billion on research every year and prides itself on being a pioneer in collaborating with scientists to bring drugs into the market. Over the last two years, Eli Lilly struck research alliances with at least four Indian companies and has increased its activities in Asia (PharmAsia News, Oct 27, 2008). Taiwo sat down with PharmAsia News' India bureau to give a lowdown on Lilly's risk-sharing strategy to shore up its new chemical entities.

You may also be interested in...



Eli Lilly Talks Up Emerging Markets, Especially China, As One Salve For Its Problems

Insisting they are not playing catch up overseas, Eli Lilly executives outlined plans for growing their business in the so-called emerging markets that are now a hot terrain - and a familiar phrase - among the biggest drug makers

Eli Lilly Talks Up Emerging Markets, Especially China, As One Salve For Its Problems

Insisting they are not playing catch up overseas, Eli Lilly executives outlined plans for growing their business in the so-called emerging markets that are now a hot terrain - and a familiar phrase - among the biggest drug makers

Merck's Chief Strategy Officer Mervyn Turner Talks To PharmAsia News About Partnerships And Transformational Research Models

Mervyn J. Turner, Merck's chief strategy officer and senior vice president for emerging markets is entrusted with the responsibility of forging research partnerships with companies across the globe. Turner evaluates pipelines and capabilities of companies that can benefit the core drug discovery functions at Merck's laboratories and as part of that function, he is building partnerships with companies in India such as Ranbaxy, Piramal Healthcare, Orchid and Advinus. On a visit to India recently, Turner sat down with PharmAsia News' India bureau to elaborate on his future ideas.

Related Content

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel